L to R: Fred Goldman and Joe ChewningIt is with great appreciation the Division of Pediatric Hematology/Oncology announces the retirement of Frederick Goldman, M.D., professor in the Division of Pediatric Hematology/Oncology and the director of the Pediatric Bone Marrow Transplant (BMT) Program at Children's of Alabama effective April 1, 2022. Dr. Goldman will remain a member of the division in a part-time capacity until September 30, 2022.
Dr. Goldman is a graduate of the Louisiana State University School of Medicine. He completed pediatric residency training at Tulane Children's Hospital and fellowship training at Denver Children's Hospital. He did a post-doctoral fellowship in immunology at the National Jewish Center for Immunology. He joined UAB in 2009, after being on faculty at the University of Iowa since 1992, where he was the director of the Pediatric BMT Program and the Pediatric Immune Disorders Program. He has successfully led our BMT Program since then delivering outstanding outcomes for our patients and expanding basic/translational research as well as access to clinical trials, including CAR-T cell treatments. The Pediatric BMT Program is FACT accredited, treating nearly 40 patients per year for a variety of malignant and non-malignant conditions, including leukemia, lymphoma, neuroblastoma, brain tumors, SCIDs, aplastic anemia, hemoglobinopathies, and metabolic disorders.
Dr. Goldman's laboratory research efforts have been focused on finding novel ways to correct disease-causing mutations using CRISPR/Cas gene editing tools and has used inducible pluripotent stem cell technology for disease modeling. He has also examined the role of telomerase and telomeres in aging, hematopoiesis, and DNA damage repair. Dr. Goldman has been recognized for clinical excellence by selection as one of the "Best Doctors in America" from 2006 to the present. We would like to congratulate Dr. Goldman on his well-deserved retirement.
The division is delighted to announce that Joe Chewning, M.D., professor in the Division of Pediatric Hematology/Oncology, will take over as the director of the Pediatric BMT and Cellular Therapy Programs effective April 1, 2022.
Dr. Chewning is a graduate of Davidson College and graduated from the University of South Carolina Medical School in 1997. After completing a pediatric residency and a chief residency year at Erlanger Hospital in Chattanooga in 2001, he trained in pediatric hematology-oncology at Memorial Sloan-Kettering Cancer Center (MSKCC). Dr. Chewning remained at MSKCC where he did an additional fellowship in pediatric bone marrow transplantation while performing human natural killer cell research. He joined the UAB Department of Pediatrics faculty in 2007.
Dr. Chewning's research focus is translational studies for the prevention and treatment of graft versus host disease. He is also interested in designing clinical research protocols for mechanisms of chronic graft versus host disease in pediatric patients undergoing hematopoietic stem cell transplantation. Dr. Chewning will continue to serve as the medical director of Patient Safety at Children’s of Alabama. Please join the division in welcoming Dr. Chewning to his new role!